The emergence of drug-resistant strains of influenza virus has catalysed a search for new antiviral agents to supplement or replace existing drugs. Following the success of the human immunodeficiency virus entry blocker Enfuvirtide, there has been a resurgence of interest in peptide-based antivirals. In this paper, we report on the discovery of a novel family of peptides (FluPep, FP) that function as inhibitors of influenza A virus infection. The prototype peptide (FP1, also known as Tkip) interacts with haemagglutinin and inhibits the binding of the virus to cell membranes. Using a plaque-reduction assay, we have demonstrated that a variety of influenza A virus subtypes (including H1N1, H3N2 and H5N1) are inhibited by FluPep and its derivatives at nanomolar concentrations. By truncating FluPep we have identified a minimal sequence of 6 aa that binds to haemagglutinin and inhibits infection. Using a mouse model of intranasal influenza virus infection, we observed potent inhibition of virus infection when peptide is given at the time of virus administration. These data indicate that FluPep is a highly effective anti-influenza agent with the potential to translate to the clinic.
INTRODUCTION
Influenza continues to be a clear and present danger to human and animal health. The ability of the virus to undergo rapid mutation means that antigenic variants constantly arise, breeching the host-adaptive immune response. Pathogenic variants may arise at any time and through reassortment can generate new subtypes with the potential to cause pandemics. A recent example of this is the 2009 H1N1 swine flu pandemic that arose in Mexico (http://www.cdc. gov/mmwR/preview/mmwrhtml/mm58d0430a2.htm) and rapidly spread around the world causing major public health concern and costing billions of US dollars to control. The periodic appearance of pandemic influenza is countered by regular seasonal flu epidemics. Although less dramatic than pandemics, seasonal influenza accounts for more than 200 000 hospitalizations (Thompson et al., 2004) and around 23 000 deaths in the USA annually (Morbidity and Mortality Weekly Report, August 27, 2010). The main strategy to combat infection is vaccination. However, due to antigenic variation and changes in global subtypes, vaccination has to be carried out annually using vaccines that contain predicted circulating strains of virus and fall short of an acceptable level of protection, particularly against novel strains. To bridge the gap between the identification of a novel virus and the availability of the vaccine, antivirals have an important role to play prophylactically and therapeutically in preventing transmission and severe illness, particularly in high-risk groups.
Current U. S. Food and Drug Administration approved antiviral drugs targeting influenza are a second line of defence, and can reduce the severity of symptoms and shorten the time-course of disease by up to 2 days. Oseltamivir (Tamiflu) and zanamivir (Relenza) are neuraminidase (NA) inhibitors that block the exit of virus from infected cells, and target influenza A and B viruses. Adamantane derivatives amantadine (Symmetrel) and rimantadine (Flumadine) block the function of the influenza A virus M2 ion channel protein (Jing et al., 2008 Approaches to broaden the availability of novel antiviral compounds include the development of synthetic peptides that disrupt the entry of virus into cells. Antiviral peptides have been developed against hepatitis C (Cheng et al., 2008) , West Nile virus (Bai et al., 2007) , respiratory syncytial virus (Budge & Graham, 2004) , human immunodeficiency virus (HIV) (Cooper & Lange, 2004) , and influenza virus (Altmann et al., 2009; Jones et al., 2006) . The clinical application of the peptide Enfuvirtide (FUZEON) that blocks the entry of HIV into cells points to the success of peptide-based therapies in a clinical setting. Other key therapeutic peptides include bivalirudin (Angiomax), a platelet aggregation inhibitor peptide and abarelix (Plenaxis), a gonadotropin-releasing hormone (GnRH) antagonist. These are typical of the new generation of peptides with excellent therapeutic efficacy.
In this study, we report on the direct antiviral properties of Tkip, a mimetic for the suppressor of cytokine signalling (SOCS) protein, which has been shown to be active in modulating inflammatory cytokine responses in pox viruses (Ahmed et al., 2009) . The finding that Tkip had antiviral properties led us to examine the antiviral properties of a range of derivative peptides that we have termed FluPep 1-9 (FP1-FP9) where FP1 is Tkip, against a number of influenza virus subtypes. We observed levels of inhibition of viral replication greater than 90 % using nanomloar concentrations of peptides, as determined by plaque-reduction assays. Levels of inhibition were greatest against H1N1 virus, including the 2009 pandemic strain, but the peptides were effective against all subtypes tested; H1N1, H3N2 and H5N1. Peptide inhibition of virus replication was a result of interactions with the viral haemagglutinin, blocking viral attachment to cells, or reattachment and infection of neighbouring cells. Therefore, these peptides provide a potent novel inhibitor of influenza virus infection.
RESULTS

Physical and chemical properties of peptides
While investigating a series of peptide structures for use as anti-inflammatory agents we identified a peptide that demonstrated potent activity against influenza A virus in vitro and in vivo. The anti-influenza peptide FP1 (also known as Tkip; Ahmed et al., 2009 ) is 12 aa long, hydrophobic and with a predicted a-helical structure as determined by PEP-FOLD predict de novo peptide structure (http://bioserv.rpbs.univ-paris-diderot.fr/PEP-FOLD). We have made several modifications to FP1 (Tkip) with a view to improving solubility, stability and antiviral activity ( Table 1) . The modified peptides all retain a predicted a-helical structure. We also examined the truncated forms of FP1 to assess the shortest peptide with antiviral activity. A summary of the different peptides used is shown in Table 1 .
Assessment of anti-influenza activity of peptide in plaque-reduction assays
The ability of various peptides to inhibit replication of influenza viruses was determined by using a plaquereduction assay on MDCK cells. Fig. 1 shows a representative assay using FP4. Assays were carried out with virus in the presence of vehicle (DMSO, 1.5 % final concentration), or virus in the presence of increasing concentrations of peptide. FP1 is highly efficient at inhibiting the mouseadapted A/WSN/33 H1N1 subtype, with an IC 50 of 0.093 mM. Modifications to this peptide to produce FP2, FP3 and FP4 resulted in improved antiviral activity against the A/WSN/33 H1N1 virus, with IC 50 values of 0.0009 mM (FP2), 0.00003 mM (FP3) and 0.00004 mM(FP4). Truncated Table 1 . Physical and chemical properties of peptides
The anti-influenza peptide (FP1, Tkip) was modified to improve solubility, stability as well as antiviral activity. Modifications from original peptide (FP1, Tkip) are underlined. Using ExPASy (the Expert Protein Analysis System) provided by the Swiss Institute of Bioinformatics (SIB), the ProtParam algorithm was used to calculate the physico-chemical parameters of peptide sequences. pI is the theoretical isoelectric point; GRAVY, grand average of hydropathicity, positive values are hydrophobic; t1/2 is estimated half-life in hours (mammalian reticulocytes, in vitro); U, unstable, S, stable. Table 2 which shows that a range of FluPep peptides have inhibitory activity with FP3 and FP4 being most effective in inhibiting virus replication. The latter two peptides are closely related differing only in the position of the RRKK (N or C termini). Consequently, we focused on these peptides in subsequent experiments.
Having established that a variety of peptides derived from FP1 were active against influenza H1 subtypes we next examined their efficacy against different haemagglutinin (HA) subtypes. We analysed the activity of FP4 against recombinant influenza A viruses. We used PR8 recombinant viruses that contain the internal genes of PR8 and the relevant influenza virus HA and NA from circulating pathogenic subtypes. In Table 2 , the IC 50 was determined for FP4 against Pr8/Vic (H3N2), Pr8/Eng09 (H1N1) and Pr8/Viet (H5N1) viruses. FP4 was effective against all three viruses with IC 50 values ranging from 0.05 to 0.13 mM.
To investigate whether FluPep was mediating its antiviral activity in a non-specific way by directly binding to the lipid envelope of the virus we carried out a plaquereduction assay with two enveloped viruses: Semliki Forest virus (SFV) and murine gammaherpesvirus (MHV-68). A range of FluPep peptides at different concentrations were incubated with SFV and MHV-68 and plaque formation monitored over 7 days. No inhibition occurred with FP1, FP2 and FP9 at concentrations in excess of 100 mM. At high concentrations of FP4 a 20 % inhibition of infectivity of MHV-68 was observed.
FluPep inhibits influenza attachment to cells
To determine the mechanism for inhibition of plaque formation we first examined whether peptides inhibited attachment of influenza virus to MDCK cells. Virus or virus plus peptide mixtures were added to chilled MDCK monolayers grown in 96-well tissue culture plates. After washing and fixing, cell-associated virus was detected with anti-influenza A antibody and HRP-conjugated secondary antibody. Increasing doses of peptide in the presence of 1.5 % DMSO inhibited adsorption of A/WSN/33 onto the cell surface of MDCK cells (Fig. 2 ). Viral attachment was completely inhibited using 6 mg (3.6 mM) FP3 ml 21 , whereas no significant inhibition of attachment was observed when cells were treated with virus and vehicle (DMSO) alone. Similar results were observed with FP1, FP2 and FP4 (data not shown). Based on these data, we propose that the antiviral activity of the peptide is due to inhibition of viral attachment to cells, acting as an entry blocker.
FluPep interacts with HA from influenza A viruses
To determine whether the ability of peptides to interfere with viral attachment was due to direct interactions with viral HA we performed peptide-binding ELISAs by using microtitre plates coated with 100 mg peptide ml 21 . Fluorescently labelled peptide was used so that binding to the plate could be confirmed microscopically (data not shown). Data show binding of rHA to all peptides tested (Fig. 3) . Differences in apparent binding efficiency are probably due to differential binding of peptide to ELISA plates. The results of this ELISA clearly show that the peptides bound specifically to influenza HA.
FluPep protect mice against a lethal dose of influenza virus
To determine if the inhibition of influenza virus replication observed in vitro translated to protection in vivo we inoculated 5-6-week-old BALB/c mice intranasally with mouse-adapted A/WSN/33 virus in the presence of peptide. Mice were monitored daily for clinical symptoms, weight was measured daily and virus titres obtained from lungs at day 7. Pre-treatment of A/WSN/33 virus with 20 mg FP4 peptide resulted in 100 % survival of mice, with no clinical indications and no loss of weight (Fig. 4a) . Modified peptides maintained antiviral activity in vivo, resulting in 2-4 log decreases in lung titres at day 7 (Fig. 4b) . This model demonstrates potent anti-influenza virus activity against A/ WSN/33 H1N1 virus when introduced prophylactically into the mouse respiratory tract. Therefore, peptides were able to protect mice from lethal H1N1 infection.
DISCUSSION
In this paper, we describe a novel family of antiviral peptides termed FluPep that are active against influenza A The ability of various peptides to inhibit influenza viruses was determined by using plaque-reduction assays on MDCK cells. Assays were carried out with mouse-adapted A/WSN/33 (H1N1) in the presence of vehicle (DMSO) or increasing concentrations of peptide, and per cent knockdown was determined. One microgram of peptide represents 0.9-1.6 mM dependent on the MW of the peptide. The antiviral activity of FP4 peptide against other subtypes of influenza virus was investigated by using plaque-reduction assays. Subtypes included H1N1 (PR8/Eng09), H3N2 (PR8/Vic) and H5N1 (PR8/Viet) recombinant viruses containing PR8 internal genes with HA and NA subtypes listed. Assays were carried out in the presence of vehicle (DMSO) or increasing concentrations of peptide by using plaquereduction assays on MDCK cells and per cent knockdown was determined. Microtitre plates coated with 100 mg peptide ml "1 were incubated with baculovirus-derived recombinant HA (California 04/2009 H1N1). Bound rHA was determined by using anti-influenza antibody, HRP-conjugated secondary antibodies and developed by using SigmaFAST OPD. Binding was calculated by determining the change in absorbance in rHA wells over DMSO/BSA alone.
Peptide
viruses in vitro and in vivo. The 12 aa peptide (Tkip, renamed FP1 in this paper to highlight its function as an anti-influenza peptide) is highly efficacious in vitro, inhibiting virus infectivity with an IC 50 in the nanomolar range. Inhibition of influenza virus also occurs with truncated peptides as small as 6 aa with an IC 50 in the micromolar range. For experiments in vitro and in vivo the peptide was solubilized in DMSO, an organic solvent widely used in clinical practice to deliver drugs, with the advantage of having a very low toxicity coupled with a mild inflammatory response. However, DMSO would not be acceptable as a vehicle for peptide delivery in the clinic and therefore in order to improve solubility in aqueous solution we modified FluPep by adding RRKK to either the N or C termini of the peptide. A reduced hydrophobicity was predicted using the ProtParam algorithm and of the resulting 16 aa peptides FP3 and FP4 proved to be more efficacious when compared with FP1 (Table 2 ). FP4 is effective at nanomolar concentrations against H1, H3 and H5 recombinant viruses determined by the plaque-reduction assay (Table 2) , and resulted in complete protection of mice challenged intranasally with virus (Fig. 4) .
The antiviral activity of Tkip was observed while investigating the anti-inflammatory activity of this SOCS mimetic (Ahmed et al., 2009) . Tkip is a tyrosine kinase inhibitor and functions by regulating the intensity of inflammatory cytokine response protecting the host against acute poxvirus infection (Altmann et al., 2009 ) and chronic autoimmune damage in the nervous system (experimental allergic encephalomyelitis) (Mujtaba et al., 2005) . The mechanism whereby FluPep mediates its antiviral activity is independent of the SOCS mimetic activity of Tkip. A key distinction between the activity of Tkip and FluPep is that the anti-inflammatory effects of Tkip can be inhibited by substituting alanine for phenylalanines at position 8 and 11 on the Tkip peptide structure (FP2) (Ahmed et al., 2009) . FP2 is more effective across a wider dose range than FP1 (Tkip) against A/WSN/33 virus and even truncated forms of the original FP1 (Tkip) 12-mer peptide showed significant antiviral activity, albeit in the micromolar range (Table 2 ).
FluPep targets HA from different subtypes of influenza A viruses and blocks the binding and uptake of the virus into cells. The initial stages of infection of cells by influenza virus involve HA binding to sialylglycoconjugates followed by protease cleavage of HA to facilitate fusion and infection of the cell. Therefore, the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage. However, peptides did not inhibit viral haemagglutination of red blood cells (RBCs). Instead, peptides alone agglutinate RBCs, even when sialic acid receptors have been removed by using bacterial sialidases (data not shown). In order to define the site(s) on HA that interact with the peptide we are carrying out X-ray crystallographic studies of HA-peptide complexes. This should provide further clues as to the mechanism of inhibition.
FluPep also inhibits infection with H3N2 and H5N1 recombinant viruses. The viruses used in this study contain the internal genes of PR8 and are thus different from those found in naturally occurring H3 and H5 viruses. Internal genes, the polymerase in particular, contribute to the virulence of H5N1 viruses and we have not yet carried out studies with highly pathogenic viruses. However, the ability of FluPep to block infection of virus with H5 surface antigen is highly likely to be important in control of these virus infections. Furthermore, it is possible that the antiinflammatory activity of FP1 and FP4 or residual antiinflammatory activity in the truncated peptides may be beneficial in highly pathogenic infections.
FluPep is part of an emerging family of peptide-based antivirals that block the entry of virus into cells. Other entry blockers recently described include peptides active against influenza virus (Jones et al., 2006) , West Nile virus (Bai et al., 2007) and HIV (Matthews et al., 2004) . The clinical application of the peptide Enfuvirtide, which blocks the entry of HIV into cells, signifies that synthetic peptides can be developed into effective antiviral drugs.
FluPep is highly effective at inhibiting influenza infection of the lung when given at the time of infection (prophylactic). Mice receiving the antiviral peptide displayed no signs of clinical disease, whereas groups given the delivery vehicle only or virus with PBS lost weight rapidly and had to be euthanized. It will be of considerable interest to determine if FluPep derivatives that retain the antiinflammatory activity identified in Tkip have an impact on lung inflammation. An agent that has both antiviral and anti-inflammatory activity would have clear benefits for use in influenza infections. This is therefore currently under investigation. FluPep's potential would also be increased by the demonstration that it could be used therapeutically so we are now extending the investigation to determine the therapeutic effect of FluPep, including approaches to prolong the half-life of the peptide in vivo. were kindly provided by Professor Wendy Barclay, Imperial College, London, UK. These are recombinant variants of A/ Puerto Rico/3/34 (PR8; NIBSC strain) that contain the PR8 core genes with the HA and NA supplied by other subtypes, which were made by a reverse genetics system as described previously (Howard et al., 2007) . Virus titres were obtained by performing standard plaque assays on MDCK cells. Briefly, serial dilutions of virus were added to confluent monolayers of cells for 1 h, 37 uC with 5 % CO 2 . Following the 1 h incubation, unadsorbed virus was removed and monolayers overlaid with the complete DMEM containing 1 % agarose and 2 mg N-acetylated trypsin (Sigma Aldrich) ml 21 and incubated at 37 uC, 5 % CO 2 for 3 days, after which time the cell monolayers were fixed with 10 % neutral buffered formalin, stained with 0.1 % toluene blue and plaques counted.
Peptides. HPLC-purified peptides were purchased from Cambridge Peptides, Cambridge, UK. Additional peptides were synthesized within the School of Chemistry, University of Edinburgh, UK. The peptide panel (see Table 1 ) included peptides containing either the amino-or carboxyl-RRKK sequence to increase solubility. FP2 has two alanine substitutions (boldface type, Table 1 ). Peptides FP7, 8 and 9 are truncated peptides. Unless otherwise stated, peptide and virus were mixed immediately prior to administration to mice or cells.
Mice and virus infections. BALB/c mice were purchased from Harlan UK Ltd (Oxon, UK). All work was carried out under a UK Home Office licence according to the Animals (Scientific Procedures) Act 1986. Five-to 6-week-old female mice were used in all experiments. Mice were anaesthetized using halothane (Rhone Merieux Ltd) or isoflurane (Merial Animal Health Ltd) and infected intranasally with 5610 3 p.f.u. of A/WSN/33 influenza virus in 40 ml PBS volume, in the presence or absence of peptide. Virus and peptide were combined immediately prior to administration to mice. Mice were weighed daily and assessed for visual signs of clinical disease, including inactivity, ruffled fur and laboured breathing. Animals that had lost 25-30 % of their original body weight were euthanized. At various times after infection, mice were euthanized by CO 2 asphyxiation, and the lungs removed, homogenized in PBS and clarified by centrifugation. Titres of infectious virus were determined by standard plaque assays on MDCK cells.
Plaque-reduction assays. Confluent monolayers of MDCK cells (ATCC) were grown in six-well dishes and infected with a dilution of virus required to obtain 250 plaques per well. Virus adsorption was carried out in the presence or absence of peptide at 37 uC with 5 % CO 2 , in a total volume of 400 ml. Virus and peptide were mixed immediately prior to addition to cells. After 1 h unbound virus and/ or peptide was removed, cells were overlaid with 1 % agarose in DMEM/N-acetylated trypsin and plaques counted after 3 days as described above.
Virus adsorption ELISA. The mouse-adapted A/WSN/33 (H1N1) virus was incubated with increasing concentrations of peptide for 1 h at 37 uC and chilled. The virus or virus and peptide solutions were plated on chilled MDCK cells in 96-well plates (50 ml per well, m.o.i of 6) for 1 h at 4 uC, washed with cold PBS, fixed with 4 % paraformaldehyde at room temperature for 30 min, washed with cold PBS and stored overnight at 4 uC. Plates were blocked with 3 % BSA in Tris-buffered saline (TBS) for 1 h at room temperature, probed with 1 : 500 dilution of polyclonal goat anti-influenza A antibody (OBT1551; AbD Serotec) for 1 h at 37 uC. Plates were washed with PBS and probed with 1 : 500 dilution of HRP-conjugated secondary antibody, donkey anti-sheep/goat IgG HRP (STAR88P; AbD Serotec) for 1 h at 37 uC, washed with PBS and developed using 200 ml per well SIGMAFast OPD (Sigma Aldrich) at room temperature for
